Products - Vital Statistics Rapid Release. - Provisional Drug Overdose Data [Internet]. 2023 [cited 2023 Oct 2]. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.

Wilson N, Kariisa M, Seth P, Smith H, Davis NL. Drug and opioid-involved overdose deaths - United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290–7.

Article  PubMed  PubMed Central  Google Scholar 

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622.

Article  PubMed  PubMed Central  Google Scholar 

Abuse NI, on D. National Institute on Drug Abuse. -- [cited 2023 Oct 2]. How effective are medications to treat opioid use disorder? https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction/efficacy-medications-opioid-use-disorder.

Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerdá M. Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.

Article  PubMed  PubMed Central  Google Scholar 

Mark TL, Goode LSA, McMurtrie G, Weinstein L, Perry RJ. Improving Research on racial disparities in Access to medications to treat opioid Use disorders. J Addict Med:https://doi.org/10.1097/ADM.0000000000001104.

Gondré-Lewis MC, Abijo T, Gondré-Lewis TA. The opioid epidemic: a Crisis disproportionately impacting Black americans and Urban communities. J Racial Ethn Health Disparities. 2023;10(4):2039–53.

Article  PubMed  Google Scholar 

Farhoudian A, Razaghi E, Hooshyari Z, Noroozi A, Pilevari A, Mokri A, et al. Barriers and facilitators to Substance Use Disorder Treatment: an overview of systematic reviews. Subst Abuse Res Treat. 2022;16:11782218221118462.

Google Scholar 

Doran KM, Rahai N, McCormack RP, Milian J, Shelley D, Rotrosen J, et al. Substance use and homelessness among emergency department patients. Drug Alcohol Depend. 2018;188:328–33.

Article  PubMed  PubMed Central  Google Scholar 

Englander H, Gregg J, Levander XA. Envisioning minimally disruptive opioid Use Disorder Care. J Gen Intern Med. 2023;38(3):799–803.

Article  PubMed  Google Scholar 

Judd H, Yaugher AC, O’Shay S, Meier CL. Understanding stigma through the lived experiences of people with opioid use disorder. Drug Alcohol Depend. 2023;249:110873.

Article  PubMed  Google Scholar 

Jakubowski A, Fox A. Defining low-threshold Buprenorphine Treatment. J Addict Med. 2020;14(2):95–8.

Article  PubMed  PubMed Central  Google Scholar 

Jakubowski A, Norton BL, Hayes BT, Gibson BE, Fitzsimmons C, Stern LS et al. Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes. J Addict Med [Internet]. 2022 Feb 8 [cited 2023 Mar 20]; https://journals.lww.com/journaladdictionmedicine/Abstract/9000/Low_threshold_Buprenorphine_Treatment_in_a_Syringe.98974.aspx.

Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abuse. 2018;39(2):167–72.

Article  Google Scholar 

Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Subst Abuse. 2020;41(3):356–64.

Article  Google Scholar 

Regis C, Gaeta JM, Mackin S, Baggett TP, Quinlan J, Taveras EM. Community Care in Reach: mobilizing harm reduction and Addiction Treatment Services for vulnerable populations. Front Public Health. 2020;8:501.

Article  PubMed  PubMed Central  Google Scholar 

Office of the Federal Register NA and RA. govinfo.gov. Office of the Federal Register, National Archives and Records Administration; 2021 [cited 2022 Sep 23]. 86 FR 33861 - Registration Requirements for Narcotic Treatment Programs With Mobile Components. https://www.govinfo.gov/app/details/FR-2021-06-28/https%3A%2F%2Fwww.govinfo.gov%2Fapp%2Fdetails%2FFR-2021-06-28%2F2021-13519.

Chan B, Hoffman KA, Bougatsos C, Grusing S, Chou R, McCarty D. Mobile methadone medication units: a brief history, scoping review and research opportunity. J Subst Abuse Treat. 2021;129:108483.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenfield L, Brady JV, Besteman KJ, De Smet A. Patient retention in mobile and fixed-site methadone maintenance treatment. Drug Alcohol Depend. 1996;42(2):125–31.

Article  CAS  PubMed  Google Scholar 

Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. J Subst Abuse Treat. 2019;103:1–8.

Article  PubMed  PubMed Central  Google Scholar 

Messmer SE, Elmes AT, Jimenez AD, Murphy AL, Guzman M, Watson DP et al. Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago. J Subst Use Addict Treat [Internet]. 2023 Apr 20 [cited 2023 May 5];0(0). https://www.jsatjournal.com/article/S2949-8759(23)00104-2/fulltext.

Hall G, Neighbors CJ, Iheoma J, Dauber S, Adams M, Culleton R, et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J Subst Abuse Treat. 2014;46(4):511–5.

Article  PubMed  Google Scholar 

Suen LW, Steiger S, Shapiro B, Castellanos S, Joshi N, Lambdin BH, et al. Get in and get out, get on with life: patient and provider perspectives on methadone van implementation for opioid use disorder treatment. Int J Drug Policy. 2023;121:104214.

Article  PubMed  Google Scholar 

Chatterjee A, Baker T, Rudorf M, Walt G, Stotz C, Martin A et al. Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions. J Subst Use Addict Treat [Internet]. 2024 Apr 1 [cited 2024 Apr 25];159. https://www.jsatjournal.com/article/S2949-8759(23)00324-7/abstract.

Fine DR, Dickins KA, Adams LD, De Las Nueces D, Weinstock K, Wright J, et al. Drug overdose mortality among people experiencing homelessness, 2003 to 2018. JAMA Netw Open. 2022;5(1):e2142676.

Article  PubMed  PubMed Central  Google Scholar 

McLaughlin MF, Li R, Carrero ND, Bain PA, Chatterjee A. Opioid use disorder treatment for people experiencing homelessness: a scoping review. Drug Alcohol Depend. 2021;224:108717.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224:108729.

Article  CAS  PubMed  Google Scholar 

Kolb E, Rueth M. Patient satisfaction with clinic-based medication pick up: addressing pharmacy-level challenges to buprenorphine access. J Opioid Manag. 2021;17(7):77–86.

Article  PubMed  Google Scholar 

Khan A, Khan Q, Kolb E. Supportive alternate site provision of buprenorphine: overcoming barriers and improving patient outcomes. J Subst Abuse Treat. 2021;123:108256.

Article  CAS  PubMed  Google Scholar 

Guadamuz JS, Wilder JR, Mouslim MC, Zenk SN, Alexander GC, Qato DM. Fewer pharmacies in black and Hispanic/Latino neighborhoods compared with White or diverse neighborhoods, 2007–15. Health Aff (Millwood). 2021;40(5):802–11.

Waiver Elimination (MAT Act) [Internet]. 2023 [cited 2023 Oct 3]. https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act.

MATE Act Training Requirements Q&A [Internet]. [cited 2023 Nov 17]. https://www.deadiversion.usdoj.gov/faq/MATE_Act_faq.htm.

Jarrett JB, Bratberg J, Burns AL, Cochran G, DiPaula BA, Legreid Dopp A, et al. Research priorities for expansion of opioid use disorder treatment in the Community Pharmacy. Subst Abuse. 2023;44(4):264–76.

Article  Google Scholar 

Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: motives for abuse, misuse, and diversion. J Subst Abuse Treat. 2019;104:148–57.

Article  PubMed  Google Scholar 

Monico LB, Mitchell SG, Gryczynski J, Schwartz RP, O’Grady KE, Olsen YK, et al. Prior experience with non-prescribed Buprenorphine: Role in Treatment Entry and Retention. J Subst Abuse Treat. 2015;57:57–62.

Article  PubMed  PubMed Central  Google Scholar 

Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39(1):51–7.

Article  PubMed  PubMed Central  Google Scholar 

Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine Treatment divide by Race/Ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–81.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz RP, Gryczynski J, O’Grady KE, Sharfstein JM, Warren G, Olsen Y, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–22.

Article  PubMed  PubMed Central  Google Scholar 

Olofsen E, Algera MH, Moss L, Dobbins RL, Groeneveld GJ, van Velzen M et al. Modeling buprenorphine reduction of fentanyl-induced respiratory depression. JCI Insight [Internet]. 2022 May 5 [cited 2023 Oct 30];7(9).